Published January 2016 | Version v1
Journal article

An investigation on the anti-tumor properties of FSH33-53-Lytic

  • 1. Zhengzhou University, Zhengzhou (China). School of Pharmaceutical Science
  • 2. Jiangsu Institute of Nuclear Medicine, Wuxi (China). Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine
  • 3. First Affiliated Hospital of Nanjing Medical University, Nanjing (China). Department of Radiation Oncology

Description

A new designed hybrid peptide FSH33-53-Lytic was synthesized and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor cell membranes disintegration. Through in vitro and vivo study, no significant enhancement on anti-tumor activity was shown compared with Lytic peptide only. We also prepared 18F-Al-NOTA-MAL-FSH33-53-Lytic and use microPET image to observe the FSHR targeting of FSH33-53-Lytic. No accumulation in the tumor may explain the failure of FSH33-53-Lytic on cancer therapy. In summary, microPET image can provide more accurate and visible information for screening new anti-tumor agents. (author)

Additional details

Publishing Information

Journal Title
Journal of Radioanalytical and Nuclear Chemistry
Journal Volume
307
Journal Issue
1
Journal Page Range
p. 89-97
ISSN
0236-5731
CODEN
JRNCDM

Optional Information

Notes
41 refs.